Technology Bundle ID
TAB-3344

Middle East Respiratory Syndrome Coronavirus Antibodies

Linked ID
E-239-2014-0
Lead Inventors
Barney Graham (NIAID)
Co-Inventors
Lingshu Wang (NIAID)
Michael Joyce (NIAID)
Wei Shi (NIAID)
Wing-pui Kong (NIAID)
Therapeutic Areas
Infectious Disease
ICs
NIAID
Middle East Respiratory Syndrome coronavirus (MERS-CoV) causes a highly lethal pulmonary infection with ~35% mortality. Currently there are no prophylactic measures or effective therapies. Inventors at the Vaccine Research Center of the National Institute of Allergy and Infectious Diseases have identified and developed neutralizing monoclonal antibodies (nMAbs) against the MERS-CoV. This invention describes antibodies that target the Spike (S) glycoprotein on the coronavirus surface, which mediates viral entry into host cells. These novel antibodies target different regions of the S protein, and when administered in combination, reduce the possibility of viral escape. In preclinical testing, these nMAbs have demonstrated potent protective effects, preventing death, viral replication in the lower airways and severe disease in challenge studies with mice. In addition, these nMAbs have potential application for use in assays for detecting MERS-CoV S protein in infected patients or animals.

This technology is available for licensing for commercial development in accordance with 35 U.S.C. § 209 and 37 CFR Part 404, as well as for further development and evaluation under a research collaboration.
Commercial Applications
  • Monoclonal antibodies developed against multiple regions of the coronavirus spike protein have potential application in the prevention and treatment of MERS-CoV. There is also potential application for their use as a diagnostic tool of infection.
Competitive Advantages
  • In vitro models, the combinations of antibodies have been demonstrated to be effective in reducing viral escape.
  • In vivo data in animal models demonstrated a potent ability to control infection.
  • Applicable in diagnostic assays

Request More Info

Licensing Contact: